<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

FAIRplus D1.01 First 3 data sets from Pilots selected and available

descriptionPublicationkeyboard_double_arrow_right Project deliverable , Other literature type , Article 01 Jan 2019 English Publisher:ZenodoFunded by:EC | FAIRplus

Authors: Gribbon, Philip; Gu, Wei; Sanz, Ferran; Ioannidis, Vassilios; Kohler, Manfred; Zaliani, Andrea; Henderson, David; +2 Authors

doi: 10.5281/zenodo.3274229 , 10.5281/zenodo.3274230

FAIRplus D1.01 First 3 data sets from Pilots selected and available

- Summary
- Subjects
- Related research
  (1)
- Metrics

Abstract

Candidate Pilot IMI projects (eTOX, ND4BB-TRANSLOCATION, ReSOLUTE, Aetionomy, OncoTrack and OPENPhacts) were initially identified based upon a long list highlighted in the DoA and through the FAIRplus partner network. Summaries of the activities and data sets available within these candidate Pilot IMI projects were collected via a survey tool, and further information was presented at the FAIRplus kick-off event by project owners. Following review, WP1 prioritized 4 IMI projects as Pilots, (eTOX, ND4BB-TRANSLOCATION, ReSOLUTE and OncoTrack). The prioritized Pilots were ratified by the General Assembly and formally selected. Each project was then assigned a key FAIRplus contact person, who worked with the data owners to identify, prioritise and release suitable data sets to the FAIRplus consortium, Squads and WP2 / 3 members. As of 30.06.2019, data sets have been released from eTOX, ND4BB-TRANSLOCATION and ReSOLUTE. OncoTrack is on course to release data in July 2019.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 802750. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation and EFPIA companies.

Related Organizations

University of Oxford
United Kingdom
University of Lausanne
Switzerland
SIB Swiss Institute of Bioinformatics
Switzerland
Novartis (Switzerland)
Switzerland
Bayer (Germany)
Germany

View all View all

Keywords

Data set, FAIRplus, FAIR-ification, FAIR, ELIXIR

1 Research products, page 1 of 1

Abstract 5036: Correlation of preclinical antitumor activity of regorafenib in CRC-PDX xenografts with gene expression and clinical parameters of the primary tumor
2017IsAmongTopNSimilarDocuments

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average